Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202402933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Jinhui Fan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, 411 Hospital of Shanghai University, Shanghai University, Shanghai, 200444, China. Hauptthemen laut MEDLINE: Liver Diseases, Nanoparticles, RNA, Drug Delivery Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 273 Literaturangaben. Gefördert von: Shanghai Oriental Talent Plan Youth Program, Baoshan District Medical Key Science (Specialty) and Specialty Brand Construction Project, Health and Family Planning Committee of Pudong New Area.
Abstract (Originalsprache)
Hepatic diseases cause serious public health problems worldwide, and there is an urgent need to develop effective therapeutic agents. In recent years, significant progress is made in RNA therapy, and RNA molecules, such as mRNAs, siRNAs, miRNAs, and RNA aptamers, are shown to provide significant advantages in the treatment of hepatic diseases. However, the drawbacks of RNAs, such as their poor biological stability, easy degradation by nucleases in vivo, low bioavailability, and low concentrations in target tissues, significantly limit the clinical application of RNA‐based drugs. Therefore, exploring and developing effective nanoscale delivery platforms for RNA therapeutics are of immense value. This review focuses on the different types of hepatic diseases and RNA therapeutics, summarizing various nanoscale delivery platforms and their strengths and weaknesses. Finally, the current status and future prospects of nanoscale delivery systems for RNA therapy are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, 411 Hospital of Shanghai University, Shanghai University, Shanghai, 200444, China.
- Department of Pharmacy, Shanghai Pudong New Area People's Hospital, Shanghai, 201200, China.
- Cancer center, Shanghai 411 hospital, China RongTong Medical Healthcare Group Co. Ltd./411 Hospital, Shanghai University, Shanghai, 200081, China.
ORCID-Profile: Tingfang Wang
Förderung
- Shanghai Oriental Talent Plan Youth Program
- Baoshan District Medical Key Science (Specialty) and Specialty Brand Construction Project
- Health and Family Planning Committee of Pudong New Area
Zitieren
APA
Fan, J., Xiao, Z., Dong, Y., Ye, F., Qiu, Y., Zhang, C., Yin, X., Li, Y., & Wang, T. (2025). Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402933
Vancouver
Fan J, Xiao Z, Dong Y, Ye F, Qiu Y, Zhang C, et al. Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402933
BibTeX
@article{Fan2025,
author = {Fan, Jinhui and Xiao, Zhicheng and Dong, Yafen and Ye, Fei and Qiu, Yan and Zhang, Chuan and Yin, Xiaolan and Li, Yi and Wang, Tingfang},
title = {Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202402933}
}
EUVIMED